Claims
- 1. A compound of the formula ##STR17## wherein: R.sup.1 is hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.4 alkenyl, cyclopropylmethyl, phenyl(C.sub.1 -C.sub.4 alkyl), naphthyl(C.sub.1 -C.sub.4 alkyl), phenyl (C.sub.1 -C.sub.4 alkyl) substituted with one or two substituents selected from the group consisting of C.sub.1 -C.sub.3 alkoxy, halo, hydroxy, C.sub.1 -C.sub.3 thioalkyl, nitro, C.sub.1 -C.sub.3 alkyl or trifluoromethyl, naphthyl(C.sub.1 -C.sub.4 alkyl) substituted with one or two substituents selected from the group consisting of C.sub.1 -C.sub.3 alkoxy, halo, hydroxy, C.sub.1 -C.sub.3 thioalkyl, nitro, C.sub.1 -C.sub.3 alkyl or trifluoromethyl, --(CH.sub.2).sub.n S(C.sub.1 -C.sub.4 alkyl), --C(O)R.sup.4, or --(CH.sub.2).sub.n C(O)NR.sup.5 R.sup.6 ;
- R.sup.2 is hydrogen, C.sub.1 -C.sub.4 alkyl, cyclopropylmethyl or C.sub.3 -C.sub.4 alkenyl;
- R.sup.3 is hydrogen, C.sub.1 -C.sub.4 alkyl or an amino blocking group;
- n is 1-4;
- R.sup.4 is hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 haloalkyl, C.sub.1 -C.sub.4 alkoxy or phenyl;
- R.sup.5 and R.sup.6 are independently hydrogen, C.sub.1 -C.sub.4 alkyl, or C.sub.5 -C.sub.8 cycloalkyl with the proviso that when one of R.sup.5 or R.sup.6 is a cycloalkyl the other is hydrogen;
- HET is a heterocyclic ring selected from the group consisting of ##STR18## where each R is independently hydrogen, C.sub.1 -C.sub.3 alkyl, halogen, hydroxy, C.sub.1 -C.sub.3 alkoxy, C.sub.1 -C.sub.3 thioalkyl, NH.sub.2, CN, or phenyl;
- or pharmaceutically acceptable salts thereof.
- 2. The compounds of claim 1 wherein R.sup.1 and R.sup.2 are independently C.sub.1 -C.sub.3 alkyl or a pharmaceutically acceptable salt thereof.
- 3. The compounds of claim 1 wherein R.sup.3 is hydrogen or a pharmaceutically acceptable salt thereof.
- 4. The compounds of claim 1 wherein R.sup.1 is --(CH.sub.2).sub.n C(O)NR.sup.5 R.sup.6 wherein n is 2, R.sup.5 is hydrogen, R.sup.6 is cyclohexyl, R.sup.2 is C.sub.1 -C.sub.3 alkyl, and R.sup.3 is hydrogen or C.sub.1 -C.sub.4 alkyl or a pharmaceutically acceptable salt thereof.
- 5. A substantially pure stereoisomer of a compound of claim 1 or a pharmaceutically acceptable salt thereof.
- 6. A substantially pure stereoisomer of a compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein the stereoisomer has R configuration at the 4-position.
- 7. A pharmaceutical formulation comprising a therapeutically effective amount of compound of claim 1 or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable excipient therefor.
- 8. A method for treating a mammal with a serotonin related disorder selected from the group consisting of anxiety, depression, excessive gastric acid secretion, hypertension, nausea and vomiting, sexual dysfunction, motion sickness, senile dementia, appetite disorders, alcoholism and smoking which comprises administering to said mammal an effective amount of a compound of claim 1 or a pharmaceutically thereof.
CROSS REFERENCE TO RELATED APPLICATIONS
The present application is a continuation-in-part application of application Ser. No. 07/677,016, filed Mar. 28, 1991 now U.S. Pat. No. 5,244,912.
US Referenced Citations (17)
Foreign Referenced Citations (10)
Number |
Date |
Country |
2064384 |
Sep 1992 |
CAX |
091328 |
Oct 1983 |
EPX |
148440 |
Jul 1985 |
EPX |
153083 |
Aug 1985 |
EPX |
162695 |
Nov 1985 |
EPX |
332968A1 |
Sep 1989 |
EPX |
506363 |
Sep 1992 |
EPX |
3525564 |
Feb 1987 |
DEX |
517732 |
Feb 1972 |
CHX |
9004396 |
May 1990 |
WOX |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
677016 |
Mar 1991 |
|